Choose Your Country or Region

NXY-059 (Disufenton sodium)

Name: NXY-059 (Disufenton sodium)
Brand: Selleck Chemicals
SKU: S6002
Rating: 5 (1 reviews)

Catalog No.S6002 Synonyms: Cerovive, Disufenton Sodium

For research use only.

NXY-059 (Cerovive, Disufenton Sodium) is a novel nitrone, shows efficacious neuroprotective effects. Phase 3.

NXY-059 (Disufenton sodium) Chemical Structure

CAS No. 168021-79-2

Selleck's NXY-059 (Disufenton sodium) has been cited by 1 Publication

Purity & Quality Control

Related Compound Libraries

Related Other Products

Telaglenastat (CB-839)^New

Telaglenastat (CB-839) is a potent, selective, and orally bioavailable glutaminase inhibitor with IC50 of 24 nM for recombinant human GAC. CB-839(Telaglenastat) inudces autophagy and has antitumor activity. Phase 1.
Setanaxib (GKT137831)^New

Setanaxib (GKT137831, GKT831) is a potent, dual NADPH oxidase NOX1/NOX4 inhibitor with Ki of 110 nM and 140 nM, respectively. Treatment with GKT137831 suppresses reactive oxygen species (ROS) production. GKT137831 partly inhibits ferroptosis.
LB-100^New

LB-100 is a water soluble protein phosphatase 2A (PP2A) inhibitor with IC50s of 0.85 μM and 3.87 μM in BxPc-3 and Panc-1 cells.
Puromycin (CL13900) 2HCl

Puromycin 2HCl (CL13900) is an aminonucleoside antibiotic, which acts as a protein synthesis inhibitor.
Cyclosporin A (NSC 290193)

Cyclosporin A (Cyclosporine A, Cyclosporine, Ciclosporin, CsA) is an immunosuppressive agent, binds to the cyclophilin and then inhibits calcineurin with IC50 of 7 nM in a cell-free assay, widely used in organ transplantation to prevent rejection.
Cyclophosphamide (NSC-26271) Monohydrate

Cyclophosphamide (NSC-26271, Cytoxan) Monohydrate is a nitrogen mustard alkylating agent, it attaches the alkyl group to the guanine base of DNA, shown to crosslink DNA, causing strand breakage and inducing mutations.
Ganciclovir (BW 759)

Ganciclovir (RS-21592, BW-759, 2'-Nor-2'-deoxyguanosine) is an antiviral drug for feline herpesvirus type-1 with IC50 of 5.2 μM in a cell-free assay.
Calcitriol (RO215535)

Calcitriol (RO215535, Topitriol, 1,25-Dihydroxyvitamin D3) is a nonselective vitamin D receptor activator/agonist(VDRA), exhibiting a 10-fold higher vitamin D receptor (VDR) binding affinity(IC50=0.4 nM) than the selective VDRA paricalcitol. Solutions are best fresh-prepared.
Ribavirin (ICN-1229)

Ribavirin (NSC-163039, ICN-1229, RTCA, Tribavirin), a synthetic guanosine analogue, possesses a broad spectrum of activity against DNA and RNA viruses.
N6-methyladenosine (m6A)

N6-methyladenosine (m6A, NSC-29409, 6-Methyladenosine, N-Methyladenosine) is a base modified analog of adenosine and is found as a minor nucleoside in natural RNAs.

Download Inhibitor Catalog

Biological Activity

Description	NXY-059 (Cerovive, Disufenton Sodium) is a novel nitrone, shows efficacious neuroprotective effects. Phase 3.
In vitro	NXY-059 is more soluble than the spin trapping agent α-phenyl-N-tert-butyl nitrone (PBN). ^[1] In an in vitro blood-brain barrier (BBB) model, 250 mM of NXY-059 administered at the onset or up to 4 h after oxygen glucose deprivation (OGD) produces a significant reduction in the increased BBB permeability caused by OGD. Furthermore, OGD produces a huge influx of tissue plasminogen activator across the BBB, which is substantially reduced by NXY-059. ^[2]
In vivo	NXY-059 reduces infarct volume in rats subjected to 2 hours of middle cerebral artery occlusion in a dose-dependent manner. At equimolar doses (3.0 mg/kg for NXY-059 and 1.4 mg/kg for PBN), NXY-059 is more efficacious than PBN. Similar results are obtained when a recovery period of 7 days is allowed. The window of therapeutic opportunity for NXY-059 is 3 to 6 hours after the start of recirculation. ^[1] NXY-059, a free radical-trapping agent, has a substantial protective effect, lessening the disability caused by an experimentally induced stroke in a primate species. NXY-059 treatment reduces the overall amount of brain damage by >50% of saline-treatment values, with similar levels of protection afforded to both white and gray matter. ^[3] Treatment with NXY-059 (50 mg/kg subcutaneous plus 8.8 mg/kg/h for 3 days subcutaneous delivered via implanted osmotic pumps) significantly decreases neurological impairment following intracerebral hemorrhage in rat, and reduces the neutrophil infiltrate observed 48 hours post-hemorrhage in the vicinity of the hematoma, and the number of TUNEL-positive cells 48 hours post-hemorrhage at the hematoma margin. ^[4]

Protocol (from reference)

Animal Research:^[1]	Animal Models: Monofilament fishing line is used to produce occlusion and neurologic deficit in male Wistar rats Dosages: 0.3, 3.0 or 30 mg/kg Administration: Administered into the right jugular vein.

References

[4] Peeling J, et al, Neuropharmacology, 2001, 40(3), 433-439.

+ Expand

Solubility (25°C)

In vitro	DMSO	76 mg/mL (199.3 mM)
	Water	76 mg/mL (199.3 mM)
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order (Data is from Selleck tests instead of citations): Saline For best results, use promptly after mixing.	30 mg/mL

Chemical Information

Molecular Weight	381.33
Formula	C₁₁H₁₃NNa₂O₇S₂
CAS No.	168021-79-2
Storage	3 years	-20°C	powder
Storage	2 years	-80°C	in solvent
Smiles	CC(C)(C)[N+](=CC1=C(C=C(C=C1)S(=O)(=O)[O-])S(=O)(=O)[O-])[O-].[Na+].[Na+]

Download NXY-059 (Disufenton sodium) SDF

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
=	×	×

Dilution Calculator Molecular Weight Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):